Why the study?
While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, data regarding elective shoulder arthroplasty are lacking.
Does perioperative continuation of clopidogrel increase blood loss and complications in patients undergoing shoulder arthroplasty?
Does perioperative continuation of clopidogrel increase blood loss and complications in patients undergoing shoulder arthroplasty?
Perioperative continuation of clopidogrel during shoulder arthroplasty is associated with increased blood loss and a trend toward more complications without a clear cardiac benefit.
May warrant perioperative caution in shoulder arthroplasty; hypothesis-generating and leaves open need for higher-level evidence.
Background While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. Methods Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty while prescribed clopidogrel. There were 33 (57%) reverse shoulder arthroplasties and 25 (43%) TSAs performed. Patients were separated into two groups based upon their use of clopidogrel in the preoperative period. Twenty patients (35%; group 1) continued clopidogrel through surgery, and 38 patients (65%; group 2) did not. The mean age was 74 years, and the mean follow-up was 42 months. Results Both groups demonstrated substantial improvements in pain and motion: visual analog scale pain improved by 7 points ( P < .001), elevation by 71° ( P < .001), external rotation by 29° ( P < .001), and internal rotation by 1.7 points ( P < .001), with no significant difference between groups. At the final follow-up, the mean American Shoulder and Elbow Surgeons score was 77 in group 1 and 86 in group 2 ( P = .067, minimum clinically important difference = 9). Estimated blood loss was 176 mL in group 1 and 127 in group 2 ( P = .02). There was one transfusion in group 1 (5%) and 0 in group 2 ( P = .16). The 90-day complication rates were 3/20 (15%) in group 1 and 0/37 in group 2 (hazard ratio = 13, P = .14). There was no statistically significant difference between groups for 30-day adverse cardiac events (2.6% and 0%, respectively, P = .46). Conclusion For the patients who continued clopidogrel preoperatively, estimated blood loss was significantly higher and trended toward a lower American Shoulder and Elbow Surgeons score (with differences meeting the minimum clinically important difference) and a higher 90-day complication rate. Perioperative continuation of clopidogrel in shoulder arthroplasty should be approached cautiously.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: